Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2025-09-08 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年半年度跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025年半年度跟踪报告' which translates to '2025 Semi-Annual Tracking Report'. It is issued by a sponsor (中信证券股份有限公司) regarding a company (上海泓博智源医药股份有限公司). The content includes detailed oversight and review activities related to the company's governance, information disclosure, fundraising, and compliance during the first half of 2025. It contains substantive information about the company's operations, internal controls, and sponsor's supervisory work, which aligns with a comprehensive interim or quarterly report rather than a brief announcement or certification. The document length is 4036 characters, which is sufficient to contain detailed financial and operational data. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-09-08 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System'. It is a detailed internal policy document outlining the principles, definitions, decision-making authority, procedures, disclosure requirements, and responsibilities related to related party transactions within the company. It references relevant laws, stock exchange rules, and regulatory guidelines. The content is focused on governance and compliance regarding related party transactions rather than financial results, audit opinions, or shareholder meeting materials. It does not contain financial statements, earnings data, or voting results. It is not a report of financial performance or an announcement but a governance and compliance policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (over 12,000 characters) and detailed procedural content support this classification with high confidence.
2025-08-27 Chinese
董事会提名委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "Board Nomination Committee Working Rules" of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the structure, responsibilities, procedures, and rules of the board nomination committee. There is no financial data, no mention of financial results, no voting results, no announcements of reports, or any other regulatory filings. The content is focused on governance practices related to board nominations and management appointments. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2534 characters, which is sufficient for a detailed governance document but too short for a full annual or interim report. Therefore, the classification is CGR with high confidence.
2025-08-27 Chinese
董事会议事规则
Governance Information Classification · 100% confidence The document is titled "董事会议事规则" which translates to "Board Meeting Rules" or "Rules of Procedure for the Board of Directors". It details the procedures, responsibilities, meeting notices, voting rules, and record-keeping related to the company's board meetings. There is no financial data, no mention of annual or quarterly reports, no audit information, no voting results, no legal proceedings, no capital changes, and no other report or announcement types. The content is focused on governance practices and internal board management rules. Therefore, the document fits the category of Governance Information (CGR). The document length is sufficient and the content is substantive, not a mere announcement or certification.
2025-08-27 Chinese
关于召开2025年第二次临时股东大会通知公告
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2025 second extraordinary general meeting of shareholders for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes information about the meeting time, location, voting procedures (both onsite and online), agenda items to be voted on, registration details, and attachments such as proxy forms and registration forms. There is no financial data or report content, but rather an announcement and instructions related to the shareholder meeting. The document length is 4661 characters, which is relatively short and consistent with a meeting notice. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. Although this is an extraordinary meeting, it falls under the same category as AGM Information. Therefore, the correct classification is AGM-R with high confidence.
2025-08-27 Chinese
关于修订《公司章程》及部分内部管理制度的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding revisions to the company's Articles of Association and some internal management systems. It details decisions made at a board meeting, including governance changes such as abolishing the supervisory board and transferring its powers to the audit committee. The document also lists various internal rules revised and notes which require shareholder approval. There is no financial data, earnings information, or detailed report content. The document is a formal announcement about governance and internal management changes, not a full governance report or annual report. It fits best under Board/Management Information (MANG) as it relates to board decisions and governance structure changes. The document length is short (1495 characters), and it is not a report publication announcement or certification. Therefore, the classification is MANG with high confidence.
2025-08-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.